. 2025 Jun;21(6):e70343.

doi: 10.1002/alz.70343.

Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

Constance Delaby^{1

2}, Aurélie Ladang³, Jose Martinez-Yriarte⁴, Chiara Zecca⁵, Giancarlo Logroscino⁵, Peter Körtvelyessy^{6

7

8}, Hayrettin Tumani⁹, Piero Parchi^{10

11}, Isabelle Quadrio¹², Melanie Hart¹³, Dorte Aalund Olsen¹⁴, Daniel Alcolea^{2

15}, Kaj Blennow¹⁶, Juan Fortea^{2

15}, Alberto Lleo^{2

15}, Alicia Algeciras-Schimnich¹⁷, Xavier Ayrignac¹⁸, Aurélie Bedel¹⁹, Gustavo A A Santos^{20

21

22}, Wyllians Borelli²³, Elodie Bouaziz-Amar²⁴, Inês Baldeiras²⁵, Edith Bigot-Corbel²⁶, Maria Bjerke²⁷, Mercedes Carretero Perez²⁸, Tiziana Casoli²⁹, Tinatin Chabrashvili³⁰, Miles D Chapman³¹, Jessica Cusato³², Erdinc Dursun³³, Anthony Fourier¹², Daniela Galimberti^{34

35}, Duygu Gezen-Ak³³, Brian A Gordon³⁶, Julien Gouju³⁷, Silvia de Las Heras Florez³⁸, Juanjo Hernandez Sanchez³⁹, Marina Herwerth⁴⁰, Daniele Imperiale³², Flora Kaczorowski¹², Kensaku Kasuga⁴¹, Ashvini Keshavan⁴², Michael Khalil⁴³, Jens Kuhle⁴⁴, Christoph Leithner⁶, Piotr Lewczuk^{45

46}, Franck Letournel³⁷, Magda Tsolaki⁴⁷, Guido Maria Giuffrè⁴⁸, Marie-Céline Blanc⁴⁹, Barbara Mroczko⁵⁰, Jose Enrique Martínez Rodríguez⁵¹, Giulia Musso⁵², Agnieszka Kulczynska-Przybik⁵⁰, Léonor Nogueira⁵³, Claire Paquet⁵⁴, Simone Baiardi^{10

11}, Lorenzo Gaetani⁵⁵, Lucilla Parnetti⁵⁵, Raquel Perez Garay⁵⁶, Koen Poesen⁵⁷, Muriel Quillard-Muraine⁵⁸, Enrique Rodriguez Borja⁵⁹, Susanna Schraen⁶⁰, Daniela Terracciano⁶¹, Franziska Bachhuber⁶¹, Steffen Halbgebauer⁹, Socrates Tzartos⁶², John Tzartos⁶³, Nadine Unterwalder⁶⁴, Lisa Vermunt⁶⁵, Cheryl L Wellington⁶⁶, Henrik Zetterberg¹⁶, Charlotte Teunissen⁶⁵, Sylvain Lehmann¹

Affiliations

¹ Univ Montpellier, LBPC-PPC, CHU Montpellier, INSERM, Montpellier, France.
² Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Clinical chemistry department, CHU de Liège, Liège, Belgium.
⁴ Clinical analysis service, Hospital do Meixoeiro, Área Sanitaria de Vigo, Vigo, Spain.
⁵ Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari "A. Moro" at Pia Fondazione "Cardinale G. Panico", Tricase, Lecce, Italy.
⁶ Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁷ Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
⁸ Labor Berlin, Division Innovation, Berlin, Germany.
⁹ CSF Laboratory, University of Ulm, Ulm, Germany.
¹⁰ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
¹¹ Department of Clinical Neurobiology, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
¹² Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon, BIORAN Team Lyon Neurosciences Research Center CNRS UMR 5292 INSERM U1028, Lyon, France.
¹³ Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.
¹⁴ Department of Biochemistry and Immunology, University hospital of southern Denmark, Odense, Southern Denmark, Denmark.
¹⁵ Department of Neurology, Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain.
¹⁶ Department of Clinical Neurochemistry, University of Gothenburg, Mölndal, Gothenburg, Sweden.
¹⁷ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
¹⁸ Department of Neurology, CHU Montpellier, INSERM, Université Montpellier, Montpellier, France.
¹⁹ Department of Biochimie, CHU de Bordeaux INSERM BRIC U1312 Université de Bordeaux, Bordeaux, France.
²⁰ Department of Surgery and Anatomy, School of Medicine of Ribeirão Preto, University of Sao Paulo, Sao Paulo, Brazil.
²¹ Department of Neurology, São Leopoldo MANDIC School of Medicine, Araras, Brazil.
²² Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, São Paulo, Brazil.
²³ Department of Biochemistry, University of Rio Grande do Sul, Porto Alegre, Brazil.
²⁴ Department of Biochemistry, Hôpital Lariboisière-Fernand Widal APHP, Université Paris Cité Paris, Paris, France.
²⁵ Faculty of Medicine of the University of Coimbra and Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
²⁶ Department of Biochimie, CHU Nantes, Nantes, France.
²⁷ Vrije Universiteit Brussel Center for Neurosciences, Department of Clinical Biology, Clinical Neurochemistry laboratory, Universitair Ziekenhuis Brussel, Brussels, Belgium.
²⁸ Department of Neurology, Santa Cruz de Tenerife, Tenerife, Spain.
²⁹ Department of Neurobiology of Ageing, IRCCS INRCA, Ancona, Italy.
³⁰ Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, USA.
³¹ Neuroimmunology and CSF laboratory, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
³² Department of Medical Sciences, UNITO, Turin, Italy.
³³ Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.
³⁴ Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
³⁵ IRCCS, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
³⁶ Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
³⁷ MINT, INSERM U1066, CNRS 6021, CHU Angers, Angers, France.
³⁸ Department of Neurology, Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife, Santa Cruz, Spain.
³⁹ Department of Neurology, Unitat de Neuroquímica, Laboratori de Referència de Catalunya, Barcelona, Spain.
⁴⁰ Neurology Department, University Hospital Zurich, Zurich, Switzerland.
⁴¹ Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
⁴² Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
⁴³ Department of Neurology, Medical University of Graz, Graz, Austria.
⁴⁴ Department of Neurology, University Hospital Basel, Basel, Switzerland.
⁴⁵ Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlagen, Erlangen, Germany.
⁴⁶ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.
⁴⁷ Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece.
⁴⁸ Department of Neuroscience, Catholic University of the Sacred Heart, Rome, Italy.
⁴⁹ Biochemistry Department, Cochin hospital, APHP, Paris, France.
⁵⁰ Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
⁵¹ Servei de Neurologia, Neuroimmunology group Hospital del Mar, IMIM, Barcelona, Spain.
⁵² Department of Medicine, University of Padova, Padova, Italy.
⁵³ UMR 5165 CNRS, CHU-PURPAN, Toulouse, France.
⁵⁴ Department of Neurologie Cognitive, Université de Paris Cité, Paris, France.
⁵⁵ Department of Neurology, University of Perugia, Perugia, Italy.
⁵⁶ Department of Clinical Analysis Service, Cruces University Hospital-OSAKIDETZA, Immunopathology Research Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
⁵⁷ Alzheimer Research Centre, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
⁵⁸ Clinical Biology Center, Rouen University Hospital, Rouen, France.
⁵⁹ Hospital Clinico Universitario de Valencia Laboratorio de Bioquimica Clínica y Patología Molecular, Valencia, Spain.
⁶⁰ Department of Biochemistry, CHU de Lille, Lille, France.
⁶¹ Department of Translational Medical Sciences, University Federico II, Naples, Italy.
⁶² Tzartos NeuroDiagnostics, Athens, Greece.
⁶³ Department of Neurology, Second Department of Neurology, National & Kapodistrian University of Athens, Athens, Greece.
⁶⁴ Department of Neurology, LaborBerlin, Berlin, Germany.
⁶⁵ Neurochemistry Laboratory, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
⁶⁶ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 40551293
PMCID: PMC12185249
DOI: 10.1002/alz.70343

Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

Constance Delaby et al. Alzheimers Dement. 2025 Jun.

. 2025 Jun;21(6):e70343.

doi: 10.1002/alz.70343.

Authors

Affiliations

¹ Univ Montpellier, LBPC-PPC, CHU Montpellier, INSERM, Montpellier, France.
² Department of Unitat de Memoria, Hospital de la Santa Creu iSant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Clinical chemistry department, CHU de Liège, Liège, Belgium.
⁴ Clinical analysis service, Hospital do Meixoeiro, Área Sanitaria de Vigo, Vigo, Spain.
⁵ Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari "A. Moro" at Pia Fondazione "Cardinale G. Panico", Tricase, Lecce, Italy.
⁶ Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁷ Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
⁸ Labor Berlin, Division Innovation, Berlin, Germany.
⁹ CSF Laboratory, University of Ulm, Ulm, Germany.
¹⁰ Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy.
¹¹ Department of Clinical Neurobiology, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
¹² Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon, BIORAN Team Lyon Neurosciences Research Center CNRS UMR 5292 INSERM U1028, Lyon, France.
¹³ Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.
¹⁴ Department of Biochemistry and Immunology, University hospital of southern Denmark, Odense, Southern Denmark, Denmark.
¹⁵ Department of Neurology, Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Barcelona, Spain.
¹⁶ Department of Clinical Neurochemistry, University of Gothenburg, Mölndal, Gothenburg, Sweden.
¹⁷ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
¹⁸ Department of Neurology, CHU Montpellier, INSERM, Université Montpellier, Montpellier, France.
¹⁹ Department of Biochimie, CHU de Bordeaux INSERM BRIC U1312 Université de Bordeaux, Bordeaux, France.
²⁰ Department of Surgery and Anatomy, School of Medicine of Ribeirão Preto, University of Sao Paulo, Sao Paulo, Brazil.
²¹ Department of Neurology, São Leopoldo MANDIC School of Medicine, Araras, Brazil.
²² Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, São Paulo, Brazil.
²³ Department of Biochemistry, University of Rio Grande do Sul, Porto Alegre, Brazil.
²⁴ Department of Biochemistry, Hôpital Lariboisière-Fernand Widal APHP, Université Paris Cité Paris, Paris, France.
²⁵ Faculty of Medicine of the University of Coimbra and Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.
²⁶ Department of Biochimie, CHU Nantes, Nantes, France.
²⁷ Vrije Universiteit Brussel Center for Neurosciences, Department of Clinical Biology, Clinical Neurochemistry laboratory, Universitair Ziekenhuis Brussel, Brussels, Belgium.
²⁸ Department of Neurology, Santa Cruz de Tenerife, Tenerife, Spain.
²⁹ Department of Neurobiology of Ageing, IRCCS INRCA, Ancona, Italy.
³⁰ Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, USA.
³¹ Neuroimmunology and CSF laboratory, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
³² Department of Medical Sciences, UNITO, Turin, Italy.
³³ Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.
³⁴ Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
³⁵ IRCCS, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
³⁶ Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
³⁷ MINT, INSERM U1066, CNRS 6021, CHU Angers, Angers, France.
³⁸ Department of Neurology, Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife, Santa Cruz, Spain.
³⁹ Department of Neurology, Unitat de Neuroquímica, Laboratori de Referència de Catalunya, Barcelona, Spain.
⁴⁰ Neurology Department, University Hospital Zurich, Zurich, Switzerland.
⁴¹ Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
⁴² Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
⁴³ Department of Neurology, Medical University of Graz, Graz, Austria.
⁴⁴ Department of Neurology, University Hospital Basel, Basel, Switzerland.
⁴⁵ Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlagen, Erlangen, Germany.
⁴⁶ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.
⁴⁷ Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece.
⁴⁸ Department of Neuroscience, Catholic University of the Sacred Heart, Rome, Italy.
⁴⁹ Biochemistry Department, Cochin hospital, APHP, Paris, France.
⁵⁰ Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
⁵¹ Servei de Neurologia, Neuroimmunology group Hospital del Mar, IMIM, Barcelona, Spain.
⁵² Department of Medicine, University of Padova, Padova, Italy.
⁵³ UMR 5165 CNRS, CHU-PURPAN, Toulouse, France.
⁵⁴ Department of Neurologie Cognitive, Université de Paris Cité, Paris, France.
⁵⁵ Department of Neurology, University of Perugia, Perugia, Italy.
⁵⁶ Department of Clinical Analysis Service, Cruces University Hospital-OSAKIDETZA, Immunopathology Research Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
⁵⁷ Alzheimer Research Centre, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
⁵⁸ Clinical Biology Center, Rouen University Hospital, Rouen, France.
⁵⁹ Hospital Clinico Universitario de Valencia Laboratorio de Bioquimica Clínica y Patología Molecular, Valencia, Spain.
⁶⁰ Department of Biochemistry, CHU de Lille, Lille, France.
⁶¹ Department of Translational Medical Sciences, University Federico II, Naples, Italy.
⁶² Tzartos NeuroDiagnostics, Athens, Greece.
⁶³ Department of Neurology, Second Department of Neurology, National & Kapodistrian University of Athens, Athens, Greece.
⁶⁴ Department of Neurology, LaborBerlin, Berlin, Germany.
⁶⁵ Neurochemistry Laboratory, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
⁶⁶ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 40551293
PMCID: PMC12185249
DOI: 10.1002/alz.70343

Abstract

Introduction: Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post-analytical methods used for NfL measurement in routine clinical practice across different contexts.

Methods: We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements.

Results: Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%).

Discussion: Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice.

Highlights: Unique international overview of current analytical and post-analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.

Keywords: biomarkers; blood; cerebrospinal fluid; clinical report; consensus approach; harmonization; neurofilaments.

PubMed Disclaimer

Conflict of interest statement

Sylvain Lehmann has served as a consultant and at advisory boards for Beckman‐Coulter, Biogen, Fujirebio, Lilly, Roche Diagnostics. Hayrettin Tumani received research support and/or honoraria for lectures and participation in adboards from Alexion, Bayer, Biogen, BMS, Chemische Fabrik Karl Bucher, GSK, Merck, Novartis, Roche, Sanofi, Siemens, Teva and Viatris, DMSG, BMBF and MWK Baden‐Württemberg, all not related to the present work. Peter Körtvelyessy received honoraria for lectures, travelling fees and participation in adboards from Roche Diagnostics, Eli Lilly, Biogen, EISAI, Novartis, EU Horizon. José M Martínez‐Yriarte received honorari for lectures from Thermofisher and Fujirebio. Giancarlo Logroscino has served as investigator for clinical trials sponsored by Biogen Pharmaceuticals, Axovant, Alector, Denali, Roche, Eisai, Genentech, Amylyx, PIAM Farmaceutici SpA. He has served as a consultant and has given Lectures for EISAI, Roche, Lilly, Piam Farmaceutici Spa, Biogen. Kensaku Kasuga received research support and/or honoraria for lectures from Eisai, not related to the present work. Xavier Ayrignac has received honoraria for lectures and participation to board from ALEXION, BIOGEN, GILEAD, JANSSEN, NOVARTIS, MERCK and ROCHE and unconditionnal research support from BIOGEN, NOVARTIS, MERCK and ROCHE. Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_212534/1), University of Basel, Progressive MS Alliance, Alnylam, Bayer, Biogen, Bristol Myers Squibb, Celgene, Immunic, Merck, Neurogenesis, Novartis, Octave Bioscience, Quanterix, Roche, Sanofi, Stata DX. Inês Baldeiras received honorari for lectures from Merck, Novartis and Fujirebio. Daniel Alcolea participated in advisory boards from Fujirebio‐Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio‐Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). Alicia Algeciras‐Schimnich has participated on advisory boards for Roche Diagnostics and Fujirebio Diagnostics. She has received speaker honoraria from Roche Diagnostics Kaj Blennow has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman‐Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. Marina Herweth served on scientific advisory boards of Biogen, Merck Serono, Alexion, Roche and Horizon Therapeutics (Amgen), received speaker's honoraria from Biogen and received travel funding from Roche. Her institution received an unrestricted research grant from Roche. She was supported by the UZH Candoc Postdoc Grant (#FK‐22‐048) by the Swiss National Science Foundation (SNSF) Ambizione Grant (PZ00’3_216616/1) and by the Olga‐Mayenfisch‐Foundation (2024). Alberto Lleo received consulting fees from Grifols S.A. and Lilly and research grants (Fondo de Investigaciones Sanitario, Carlos III Health Institute, Alzheimer's Association, Ajuntament de Barcelona, en colaboracion con la Fundació La Caixa). Juan Fortea received consulting fees from AC Immune, Alzheon, Zambon, Lilly, Roche, Eisai, Perha and research grants (Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III. Spain, National Institutes of Health (NIH) USA, Generalitat de Catalunya Spain, Fundació Tatiana Pérez de Guzmán el Bueno Spain, Alzheimer´s Association USA, Brightfocus USA, Horizon 2020, European Commission). C.Teunissen has research contracts with Acumen, ADx Neurosciences, AC‐Immune, Alamar, Aribio, Axon Neurosciences, Beckman‐Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N diagnostics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. She is editor in chief of Alzheimer Research and Therapy, and serves on editorial boards of Molecular Neurodegeneration, Alzheimer's & Dementia, Neurology: Neuroimmunology & Neuroinflammation, Medidact Neurologie/Springer, and serves on committee to define guidelines for Cognitive disturbances, and one for acute Neurology in the Netherlands. She had consultancy/speaker contracts for Aribio, Biogen, Beckman‐Coulter, Cognition Therapeutics, Eli Lilly, Merck, Novo Nordisk, Olink, Roche and Veravas. Michael Khalil has received travel funding and speaker honoraria from Bayer, Biogen, Novartis, Merck, Sanofi and Teva and serves on scientific advisory boards for Biogen, Bristol‐Myers Squibb, Gilead, Merck, Neuraxpharm, Novartis, Alexion, Amgen and Roche. He received research grants from Biogen, Novartis and Teva. All other authors declare that they have no competing interests and nothing to disclose. Author disclosures are available in the Supporting Information.

Figures

**FIGURE 1**
(A) The COU across participating centers. (B) An overview of the biological fluids utilized for NfL assessment across the participating centers. (C–E) The post‐analytical analysis of NfL measurements, specifically addressing the clinical data used for result interpretation (C), the definition of cutoff values (D), and the reporting of results (E). COU, context of use; NfL, neurofilament light chain.

See this image and copyright information in PMC

References

1. Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9:a018309. doi: 10.1101/cshperspect.a018309 - DOI - PMC - PubMed
1. Bocquet A, Berges R, Frank R, Robert P, Peterson AC, Eyer J. Neurofilaments bind tubulin and modulate its polymerization. J Neurosci. 2009;29:11043‐11054. doi: 10.1523/JNEUROSCI.1924-09.2009 - DOI - PMC - PubMed
1. Vineethakumari C, Lüders J. Microtubule anchoring: attaching dynamic polymers to cellular structures. Front Cell Dev Biol. 2022;10:867870. doi: 10.3389/fcell.2022.867870 - DOI - PMC - PubMed
1. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577‐589. doi: 10.1038/s41582-018-0058-z - DOI - PubMed
1. Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders—towards clinical application. Nat Rev Neurol. 2024;20:269‐287. doi: 10.1038/s41582-024-00955-x - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

Affiliations

Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Figures

Similar articles

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical